Generic filters

CYBN – Cybin Inc


The company is Shariah Compliant, according to AAOIFI methodology.

Cybin Inc. (Cybin) is a clinical-stage biopharmaceutical company. The Company is engaged in creating psychedelic-based therapeutics to address the unmet need for new treatment options for people who suffer from mental health conditions. Its development pipeline consists of deuterated psilocybin analog program (CYB003), deuterated dimethyltryptamine program (CYB004), phenethylamine derivatives program (CYB005), and technology programs. The Company is engaged in developing CYB003, a deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The Company’s CYB005 is focused on the development of therapeutic phenethylamine derivatives for the treatment of potential neuroinflammation and other neurological conditions. Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.


Debt ÷ Market cap (MC)0
Non-Compliant Assets ÷ MC
Impure Income (incl. Interest)0.66
Impure Income%
Interest Income0.66%